Gujarat Kidney And Super Speciality peers

Companies like Gujarat Kidney And Super Specialitylatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GKSL₹171.87

Gujarat Kidney And Super Speciality Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHSHALBYINDRAMEDCOLOTUSEYEARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹1,355 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
GKSL
FY26
GPTHEALTH
FY26
SHALBY
FY26
INDRAMEDCO
FY26
Peer
Average
Valuation — at last close
P/E69.02×26.58×37.76×◆ 15.89×26.74× +158%
P/B5.37×4.17×◆ 1.30×3.94×3.14× +71%
EV/EBITDA48.88×12.97×12.38×◆ 9.95×11.77× +315%
Market Cap₹1,355 Cr₹1,123 Cr₹1,311 Cr₹2,918 Cr₹1,784 Cr -24%
Growth
Revenue CAGR 3Y——◆ 12.35%10.50%11.43%
Revenue CAGR 5Y———19.30%19.30%
Net Income CAGR 3Y——-19.97%◆ 28.69%4.36%
Revenue YoY (latest Q)—◆ 17.83%11.74%8.35%12.64%
Net Income YoY (latest Q)—◆ 65.73%36.70%8.33%36.92%
Profitability
EBITDA Margin◆ 32.85%17.81%12.51%18.00%16.11% +104%
Net Income Margin◆ 20.50%8.93%3.04%12.39%8.12% +152%
Return on Common Equity6.14%16.32%3.74%◆ 27.47%15.84% -61%
Return on Capital Employed8.24%16.42%5.79%◆ 29.88%17.36% -53%
Return on Assets5.65%9.95%1.96%◆ 19.93%10.61% -47%
Credit & Quality
Total Debt/Equity0.06×0.06×0.54×◆ 0.00×0.20× -70%
Interest Coverage11.84×6.93×1.87×◆ 37.09×15.30× -23%
Scale — latest FY
Revenue / Total Income₹82 Cr₹473 Cr₹1,141 Cr₹1,483 Cr₹1,032 Cr -92%
Net Income₹16.8 Cr₹42.2 Cr₹34.7 Cr₹184 Cr₹86.8 Cr -81%
Total Assets₹298 Cr₹465 Cr₹1,839 Cr₹991 Cr₹1,098 Cr -73%
EPS₹2.49₹5.15₹3.23₹20.03₹9.47 -74%
Book Value per Share₹32.03₹32.84₹93.49₹80.76₹69.03 -54%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.